Ruffer LLP Sells 792,785 Shares of Pfizer Inc. $PFE

Key Points

• Ruffer LLP has reduced its stake in Pfizer Inc. by 36.2%, selling 792,785 shares and now holding 1,399,513 shares, making it the 16th largest position in their portfolio.
• Pfizer reported better-than-expected earnings of $0.78 per share with revenues of $14.65 billion, surpassing analysts' estimates.
• Recent analyst ratings for Pfizer show a mix of upgrades and downgrades, with an average rating of "Hold" and a consensus price target of $28.12.

Ruffer LLP cut its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 36.2% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,399,513 shares of the biopharmaceutical company's stock after selling 792,785 shares during the period. Pfizer comprises approximately 1.5% of Ruffer LLP's investment portfolio, making the stock its 16th largest holding. Ruffer LLP's holdings in Pfizer were worth $33,923,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also bought and sold shares of PFE. Brighton Jones LLC lifted its stake in Pfizer by 1,282.4% during the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company's stock valued at $17,677,000 after acquiring an additional 618,117 shares in the last quarter. Revolve Wealth Partners LLC lifted its stake in Pfizer by 12.5% during the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company's stock valued at $498,000 after acquiring an additional 2,087 shares in the last quarter. Vident Advisory LLC bought a new position in Pfizer during the 4th quarter valued at $248,000. Heck Capital Advisors LLC bought a new position in Pfizer during the 4th quarter valued at $49,000. Finally, Park Square Financial Group LLC bought a new position in Pfizer during the 4th quarter valued at $128,000. 68.36% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

PFE has been the topic of several research analyst reports. Morgan Stanley boosted their price objective on Pfizer from $32.00 to $33.00 and gave the stock an "equal weight" rating in a research report on Wednesday, August 6th. Berenberg Bank cut their price objective on Pfizer from $28.00 to $25.00 and set a "hold" rating on the stock in a research report on Thursday, May 29th. Bank of America boosted their price objective on Pfizer from $27.00 to $28.00 and gave the stock a "neutral" rating in a research report on Wednesday, August 6th. Citigroup boosted their price objective on Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a research report on Wednesday, August 6th. Finally, Wall Street Zen raised Pfizer from a "hold" rating to a "buy" rating in a research report on Saturday, September 20th. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $28.12.

Pfizer Stock Performance

Shares of PFE opened at $24.07 on Thursday. The stock's 50-day simple moving average is $24.59 and its 200 day simple moving average is $24.18. The stock has a market capitalization of $136.82 billion, a price-to-earnings ratio of 12.80, a price-to-earnings-growth ratio of 0.85 and a beta of 0.55. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $30.43.

Pfizer (NYSE:PFE - Get Free Report) last announced its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping analysts' consensus estimates of $0.58 by $0.20. The business had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The company's quarterly revenue was up 10.3% compared to the same quarter last year. During the same period in the prior year, the company earned $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.